Expression of Stress Markers During Meth Treatment (EXPRESS+)

Description

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Conditions

Substance-Related Disorders, HIV

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder

Expression of Stress Markers During Meth Treatment (EXPRESS+)

Condition
Substance-Related Disorders
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA Vine Street Clinic, Los Angeles, California, United States, 90038

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Assigned male sex at birth
  • 2. 18 to 45 years of age
  • 3. Reports having sex with men in the past 12 months.
  • 4. HIV-positive (confirmed by certification or by HIV rapid test)
  • 5. Has an HIV care provider (last seen in the past 12 months)
  • 6. Has a current antiretroviral prescription
  • 7. Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5
  • 8. Urine test is positive for methamphetamine within 30 days of their screening visit
  • 9. Seeking treatment for methamphetamine use disorder.
  • 10. Ability to attend twice weekly appointments for drug testing and treatment
  • 1. Assigned male sex at birth
  • 2. 18 to 45 years of age
  • 3. Reports having sex with men in the past 12 months.
  • 4. HIV-positive (confirmed by certification or by HIV rapid test)
  • 5. Has an HIV care provider (last seen in the past 12 months)
  • 6. Has a current antiretroviral prescription
  • 1. Identifies as (cis- or transgender) female
  • 2. Reports another current or past substance use disorder
  • 3. Reports being in another intervention or clinical trial for substance use
  • 4. Positive test for opioids, cocaine, and/or MDMA
  • 1. Identifies as (cis- or transgender) female
  • 2. Positive test for methamphetamine, opioids, cocaine, and/or MDMA.
  • 3. Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
  • 4. Reports past or current substance use disorder

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, Los Angeles,

Michael J Li, PhD, PRINCIPAL_INVESTIGATOR, UCLA Department of Family Medicine

Study Record Dates

2026-03-31